Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 3Sarcoma 2Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Follicular 17Lymphoma, Large B-Cell, Diffuse 9Sarcoma 7Lymphoma, B-Cell 7Lymphoma, Non-Hodgkin 6Rhabdoid Tumor 5Lymphoma 5Sarcoma, Synovial 4Prostatic Neoplasms 4Recurrence 3Mesothelioma 3Lymphoma, Mantle-Cell 3Wilms Tumor 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Hematologic Neoplasms 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1

Interventions

Pemetrexed 39Cisplatin 33pembrolizumab 21Nivolumab 17Carboplatin 16Ipilimumab 13Gemcitabine 10Cyclophosphamide 9fludarabine 6durvalumab 6Bevacizumab 6Radiotherapy, Intensity-Modulated 4LMB-100 4Dexamethasone 4tremelimumab 3tazemetostat 3spartalizumab 3olaparib 3niraparib 3atezolizumab 3anetumab ravtansine 3amatuximab 3Vinorelbine 3Paclitaxel 3Imatinib Mesylate 3Cerebral Decortication 3tislelizumab 2sargramostim 2fludarabine phosphate 2defactinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Mesothelioma × tazemetostat × Clear all
NCT02875548 2025-11-04

TRuST

Ipsen

Phase 1/2 Completed
58 enrolled
LymphoidOther solid neoplasmSarcomaThoracic

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mesothelioma, Sarcoma, Synovial, Lymphoma, Large B-Cell, Diffuse

NCT04537715 2025-02-19

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

Ipsen

Phase 1 Completed
42 enrolled 39 charts
LymphoidOther hematologic neoplasmOther solid neoplasmSarcomaThoracic

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mesothelioma, Sarcoma, Sarcoma, Synovial, Lymphoma, Large B-Cell, Diffuse, Rhabdoid Tumor, Hematologic Neoplasms

NCT02860286 2021-04-09

Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

Epizyme, Inc.

Phase 2 Completed
74 enrolled 23 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡